Enanta Pharmaceuticals reported the appointment of Mark G. Foletta to its Board of Directors. Foletta will also serve as the Chair of the Audit Committee and will be a member of the Nominating and Corporate Governance Committee. The appointment of Foletta increases the number of Enanta Directors to seven. Most recently, Foletta was Executive Vice President and Chief Financial Officer of Tocagen, a clinical-stage biopharmaceutical company focused on advancing a cancer-selective gene therapy platform, prior to its merger with Forte Biosciences.